Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Benzinga

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

Benzinga

Weight loss: Weekly jab tricks body into feeling full and causes 24kg drop

Participants in the trial lost an average of 22.5 per cent of their body weight. This is more than twice the normal effectiveness of such treatments and could be an alternative to surgery for people living with obesity.

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Mower, co-inventor of implantable defibrillator, dies at 89

A cardiologist who helped invent an automatic implantable defibrillator that has helped countless heart patients live longer and healthier has died

The Independent UK

Analyst Ratings for Eli Lilly

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Benzinga

Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.

Benzinga

Eli Lilly Whale Trades For April 28

Benzinga's options scanner just detected over 16 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $701,114. At the same time, our algo caught 4 for a total amount of 146,845.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Benzinga

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Benzinga

Peering Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has fallen 12.05% since its last report. The company recently reported that it has 5.79 million shares sold short, which is 0.73% of all regular shares that are available for trading.

Benzinga

Eli Lilly: Q1 Earnings Insights

Eli Lilly (NYSE:LLY) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:25 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview For Eli Lilly

Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Eli Lilly will report an earnings per share (EPS) of $2.13.

Benzinga

How To Attend Eli Lilly Q1 2022 Earnings Conference Call

Eli Lilly (NYSE:LLY) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. How to Attend Eli Lilly (LLY) Conference Call Follow this link to access the live webcast.

Benzinga

Executives Sell Over $44M Of 4 Stocks

Although gold futures traded slightly lower on Friday, there were a few notable insider trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 37 strange trades.

Benzinga

Where Eli Lilly Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

The Independent UK

US pulls GSK's COVID drug as omicron sibling dominates cases

U.S. regulators say GlaxoSmithKline’s COVID-19 antibody drug should no longer be used because it is likely ineffective against the latest version of the virus that accounts for most cases

Benzinga

Alphabet And 2 Other Stocks Insiders Are Selling

Although the Nasdaq Composite dropped around 2% on Tuesday, there were a few notable insider trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Peering Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 22.39% since its last report. The company recently reported that it has 6.50 million shares sold short, which is 0.82% of all regular shares that are available for trading.

Benzinga

If You Invested $100 In Eli Lilly 10 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.2% on an annualized basis producing an average annual return of 21.76%. Currently, Eli Lilly has a market capitalization of $274.87 billion.

Financial Times

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Benzinga

Looking Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 13.56% since its last report. The company recently reported that it has 5.36 million shares sold short, which is 0.67% of all regular shares that are available for trading.

Benzinga

Check Out What Whales Are Doing With LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Benzinga

Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis.

1 … 25 26 27 28

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Eli Lilly and Company

ZoomInfo Technologies Inc

14 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.